A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (AWARD-10)

H9X-MC-GBGE -

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
Dulaglutide, Metformin, SGLT2 inhibitor
Could I receive a Placebo?
Yes
Enrollment Goal
424
Trial Dates
Nov 1, 2015 - Feb 1, 2017
How long will I be in the trial?
Your participation could last up to 38 weeks and include 11 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.